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Abstract:  The characterization of regulatory T cells (Treg) during HIV infection has become of particular interest 
considering their potential role in the pathogenesis of the acquired immunodeficiency syndrome. Different reports on 
Tregs in HIV-infected patients vary greatly, depending on the state of disease progression, anatomical compartment, and 
the phenotypic markers used to define this cell subpopulation. To determine the frequency of Tregs we included paired 
samples from peripheral blood and rectal biopsies from controls and chronic HIV patients with or without detectable viral 
load. Tregs were determined by flow cytometry using three different protocols: CD4
+Foxp3
+; CD4
+Foxp3
+CD127
Low/-, 
and CD4
+CD25
+CD127
Low/-.
 In addition, and with the purpose to compare the different protocols we also characterized 
Tregs in peripheral blood of HIV negative individuals with influenza like symptoms. Here, we report that Treg 
characterization in HIV-infected patients as CD4
+Foxp3
+ and CD4
+Foxp3
+CD127
Low/- cells was similar, indicating that 
both protocols represent a suitable method to determine the frequency of Tregs in peripheral blood mononuclear cells 
(PBMC) and gut associated lymphoid tissue (GALT). In contrast, in HIV but not in flu-like patients, detection of Tregs as 
CD4
+CD25
+CD127
Low/- cells resulted in a significantly lower percentage of these cells. In both, HIV patients and controls 
the frequency of Treg was significantly higher in GALT compared to PBMC. The frequency of Tregs in PBMC and 
GALT using CD4
+Foxp3
+ and CD4
+Foxp3
+CD127
Low/- was higher in HIV patients than in controls. Similarly, the 
frequency of Treg using any protocol was higher in flu-like patients compared to controls. The results suggest that relying 
on the expression of CD25 could be unsuitable to characterize Tregs in PBMC and GALT samples from a chronic 
infection such as HIV. 
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INTRODUCTION 
  Regulatory T cells (Treg) play a major role in 
maintaining self-tolerance and limiting antiviral responses 
during chronic infections. Treg is a subpopulation of CD4
+ T 
cells characterized by their potent capacity to reduce the 
activation and expansion of conventional T cells (Tcon) [1, 
2]. Considering that immune activation is a hallmark of 
human immunodeficiency virus type-1 (HIV) infection, a 
considerable number of studies have explored the role of 
Treg in different cohorts of patients, reporting contradictory 
data. In peripheral blood, several studies have reported a 
reduction in the percentage of Treg in HIV patients, 
independent of viral load, compared to controls [3,4]; in 
contrast, other reports indicate either an increase in this T 
cell subpopulation [5-8] or no change [9,10]. Although 
several factors, including the stage of infection and the 
heterogeneity of the HIV populations studied can account for 
these differences, technical considerations in the phenotypic 
characterization of these cells cannot be ruled out. The first 
concern is that most of the original reports indicating 
frequency and absolute counts of Treg in HIV patients were 
based on the assumption that a high level of CD25 
expression is a reliable marker for human Treg [11, 12]. 
There is no doubt that the CD4
+CD25
hi T cell subset has the  
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greatest regulatory potential [13]; however, there is also 
evidence that activated conventional cells have upregulated 
the CD25 molecule [14]. 
  A better characterization was achieved by determining 
the expression of Foxp3, the best marker so far identified to 
characterize this cell subpopulation; however, this molecule 
is also transiently  expressed in a small percentage of 
activated CD4
+ Tcon, and it is not convenient to purify the 
cells because its detection implies permeabilization [15]. 
Later, in 2006 the absence or low expression of the alpha 
chain of the IL-7 receptor, the CD127 molecule, along with 
the expression of the transcription factor Foxp3, were 
considered the most specific markers of this cell population 
[13, 16]. 
  Although flow cytometry is an efficient tool to determine 
the phenotype and functional activity of Treg [13, 16, 17], 
there is still some controversy regarding the molecules used 
for their characterization, particularly in the context of 
chronic infections [18]. In addition, most of the immune 
alterations occurring during HIV infection have been well 
documented in peripheral blood. However this virus has a 
greater impact in lymphoid organs, particularly in GALT, the 
main site of HIV replication [19], where little is known 
regarding Treg phenotype. In this study we compared three 
different protocols to characterize Tregs. We included 
samples from peripheral blood and gut associated lymphoid 
tissue (GALT) of healthy controls and two groups of 
chronically HIV infected patients: patients with viral load 
and patients with undetectable viral load. Here, we explore if 50    The Open Virology Journal, 2012, Volume 6  Rueda et al. 
type of tissue sample or the virus influence the Treg 
phenotypic alteration. In addition, and with the purpose of 
determining whether changes in Treg are specific of HIV 
infection or associated to any inflammatory/activation 
process due to any infection, we also characterized Tregs in 
peripheral blood of HIV negative individuals with influenza 
like symptoms. The results suggest that relying on the 
expression of CD25 is unsuitable to characterize Tregs in 
peripheral blood mononuclear cells (PBMC) and GALT 
samples from HIV patients. 
MATERIALS AND METHODS 
Subjects 
  Four groups of subjects, from Medellin, Colombia, were 
included in the study: HIV negative healthy controls (HC, 
n=10); HIV negative individuals with acute flu-like 
symptoms (Flu, n=9); chronic HIV-1-infected patients with 
undetectable viral load (HIV-U, n=13) and HIV-1-infected 
patients with viral load (HIV-VL, n=19). Flu-like patients 
had an average of five days with symptoms such as fever, 
malaise, headache, sore throat, nasal congestion and 
weakness; all patients had rapid spontaneous resolution of 
the disease in absence of treatment. To rule out bacterial 
infection, para-clinical examinations were carried-out. 
Healthy controls and flu-like patients were screened to rule 
out HIV infection by electrochemiluminescence (HIV combi 
PT, Roche Diagnostics; Mannheim, Germany). 
  HIV patients, with at least two years of confirmed 
infection, classified in the B clinical category, according to 
the CDC criteria were included. The demographic and 
clinical characteristics of these individuals are shown in 
Table  1. Absolute number and percentage of CD4
+ T-cell 
were calculated in whole blood samples. Plasma HIV-1 
RNA levels were assessed by RT-PCRq (COBAS 
AmpliPrep/ COBAS TaqMan, Roche Molecular). 
Isolation of Cells from Peripheral Blood and GALT 
  PBMC were obtained from 10 ml of heparin venous 
blood samples by centrifugation on Histopaque (Sigma-
Aldrich, St Louis, MO, USA) for 30 min at 400 x g. Mucosal 
samples were processed as described by the Shacklett 
protocol [20] with minor modiﬁcations. Rectal tissue was 
obtained by rectosigmoidoscopy from the rectum at 10 cm 
from the anal verge. A flexible sigmoidoscope with a single 
endoscopy biopsy forcep FB-24K-1 (Olimpus America 
Corp, Melville, NY, USA) was used. Samples were 
processed by digestion using collagenase type II from 
Clostridium histolyticum (Sigma) at 0.5 mg/ml diluted in 
RPMI 1640 and 7.5% FCS (fetal calf serum) (penicillin 100 
U/ml, streptomycin 100 g/ml, amphotericine B 0.25 g/ml) 
(Gibco-BRL; Grand Island, NY, USA), during 30 min at 
37ºC while shaking. After collagenase digestion, biopsy 
fragments were further disrupted by repeated passage 
through a 30 ml syringe with a blunt ended 16 gauge needle 
(Stem Cell Technologies, Vancouver, BC). Rectal cells (RC) 
were isolated by passage through a nylon strainer of 70 M 
(Falcon, Lincoln Park, NJ, USA). PBMC and RC were 
washed with Dulbeco´s phosphate buffered saline (DPBS) 
(Sigma-Aldrich; St Louis, MO, USA) to remove excess 
histopaque and collagenase, respectively. 
Flow Cytometry Analysis of PBMC and RC 
  PBMC and RC were treated with 20 ug/ml of human IgG 
(Sigma-Aldrich; St Louis, MO, USA) to block Fc receptors, 
and stained on the surface with anti-CD4-ECD (clone 
SFCI12T4D11) (Beckman Coulter Fullerton, CA, USA) 
anti-CD3-PE-CY7 (clone UCHT1), anti-CD25-PE-CY5 
(clone BC96) and anti-CD127-PE (IL-7 R, clone RDR5) (e-
Bioscience, San Diego, CA, USA) for 30 min at 4°C. The 
cells were washed with DPBS, then fixed/permeabilized 
(Foxp3 staining buffer kit, e-Bioscience) and stained 
intracellularly using monoclonal antibodies against anti-
Foxp3-FITC (clone PCH101), for 30 min at 4°C. At least 
100,000 events were acquired for each sample in the 
lymphocyte region, using the flow cytometry FC500 
(Beckman Coulter Fullerton, CA), and analyzed using the 
Kaluza Software (Beckman Coulter Fullerton, CA). T cells 
were gated first based on forward- and side-scatter 
properties, then as CD3
+CD4
+ cells (Fig. 1A). The strategy 
followed to detect Treg was previously reported by Presicce 
et al., 2010 [21] and Seddiki et al., 2006a [16] protocols. 
Briefly, to define the limit of the positive gate, a negative 
biological population (CD3
-CD4
- or CD3
+CD4
-), previously 
known for not expressing the marker of interest, was used 
[21]; the Mean fluorescence intensity (MFI) was analyzed 
within the positive population. 
Statistical Analysis 
  Statistical analyses were performed using GraphPad 
Prism 5 (San Diego, CA, USA). The data are shown as 
median (25th percentile-75th percentile). Comparisons of 
medians among groups were performed by the U-Mann-
Whitney test or the Kruskal Wallis test with Dunn’s multiple 
comparisons post-test. Intragroup comparisons were made 
Table 1.  Characteristics of Healthy Controls, Flu-Like, HIV with and Undetectable Viral Load 
 
  Healthy Controls (n=10)  Flu-Like (n=9)  HIV Undetectable Viral Load (n=13)  HIV With Viral Load  (n=19) 
Age (years)
1  46 (13)  30(7)  42 (9)  38 (12) 
% Male/Female  50/50  45/55  85/15   95/5 
% CD4
+ T cell
2  39 (32-46)  34 (32-41)  16** (12-31) 18*** (10-24) 
% CD8
+ T cell
2 20  (16-23)  32
¥ (22-34) 45*** (34-56) 46*** (42-57) 
HIV Viral load (copies/ml)
2  N/A N/A  <40  (40-40)  12500^ (230-50190) 
1Results are expressed as mean (SE); 
2Results are expressed as median (25th-75th percentiles). Groups were compared by the Kruskal-Wallis test and the Dunn´s multiple 
comparison post-test. Significant differences are indicated by **p<0.01, ***p<0.001compared to helthy control group and p<0.01 with the flu-like group. Comparation by U Mann 
Whitney test between controls and flu groups are indicated by
 ¥p<0.01 and between both groups of HIV-1 positive patients by ^ p<0.001. N/A: not applicable. Low Frequencies of CD25+ Treg During HIV Infection  The Open Virology Journal, 2012, Volume 6    51 
with Friedmann test. Correlations were made with spearman 
test and p  values less than 0.05 were considered to be 
statistically significant. 
RESULTS 
Patient Characteristics 
  As shown in Table 1, the percentage of CD4
+ T cells 
were reduced in both groups of HIV patients (with detectable 
and undetectable viral load) compared to controls (HC vs 
HIV-U; p<0.01) (HC vs HIV-VL; p<0.001) and flu-like 
(both p<0.01). Controls, flu-like, HIV-U and HIV-VL 
exhibit CD4
+  T cell counts of 905 cells/mm
3 (692-1093 
cells/mm
3), 815 cells/mm
3 (645-923 cells/mm
3), 439 
cells/mm
3(301-986 cells/mm
3) and 426 cells/mm
3 (287-707 
cells/mm
3), respectively. The CD4
+  T cell counts were 
strikingly low in the HIV-VL group compared with controls 
(p<0.05). As expected, the percentages of CD8
+ T-cells were 
higher in all individuals with viral infection (HIV and Flu) 
compared to controls, with the highest values found in both 
HIV groups (Table 1). All the patients with undetectable 
viral load had been on highly active antiretroviral therapy 
(HAART) for a median of 8 (3-12) years. 
 
Fig. (1). Chacterization of Treg phenotype. Staining of Treg was made with conjugated monoclonal anti-CD3-PE-CY7, anti-CD4-ECD, 
anti-CD25-PE-CY5, anti-CD127-PE and anti-Foxp3-FITC antibodies. A) Scatter blot from one representative figure of flow cytometry data 
shows the frequency of Treg in PBMC in an individual from a healthy control group. Three different ways of defyning Treg were analyzed: 
CD4
+Foxp3
+ (right panel), CD4
+Foxp3
+CD127
Low/- (middle panel) and CD4
+CD25
+CD127
Low/-(left panel). In the Foxp3
+ gate the following 
analysis were done. B) percentage and MFI of CD25 molecule; and C) MFI of Foxp3. 
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Low Frequency of CD4
+CD25
+CD127
Low/- Tregs Detected 
During Chronic HIV Infection in Peripheral Blood and 
Gastrointestinal Tissue 
  To characterize the Treg subset during HIV infection, we 
analyzed the frequency of Treg using the following 
protocols: i) CD4
+Foxp3
+; ii) CD4
+Foxp3
+CD127
Low/-; and 
iii) CD4
+CD25
+CD127
Low/- (Fig. 1A) as reported by Seddiki 
et al., [16]. As shown in Fig. (2A), the percentage of Treg in 
PBMC from healthy donors (upper panel) and flu-like 
patients was similar intra-group, regardless of the protocol 
used. In contrast, the percentage of Treg from HIV samples 
varied depending of the protocol. In the HIV-U group the 
frequency was similar, 7% (6-10%) and 7% (5-8%) when the 
Treg were defined as CD4
+Foxp3
+, and CD4
+Foxp3
+ 
CD127
Low/-respectively; however, the frequency was 
significantly lower, only 4% (4-6%), when these cells were 
defined as CD4
+CD25
+CD127
Low/-  (Fig.  2A; p<0.05 
compared to CD4
+Foxp3
+). Similarly, in the HIV-VL group 
the frequency of Treg was 7% (6-10%) and 6% (5-8%) when 
the Treg were defined as CD4
+Foxp3
+, and 
CD4
+Foxp3
+CD127
Low/-  respectively; however, the 
frequency was lower with the CD4
+CD25
+CD127
Low/- 
protocol compared to CD4
+Foxp3
+  (5% (4-8%) vs 7% (6-
10%); p<0.001) (Fig. 2A). 
  Interestingly, and probably due to an inflammatory 
process in both, chronic (HIV: using CD4
+Foxp3
+, 
CD4
+Foxp3
+CD127
Low/- protocol) and acute (flu-like: using 
any protocol) viral infections, the percentage of Treg on 
PBMC was increased compared with controls (p<0.05) (Fig. 
2A). However, when the Treg were defined as 
CD4
+CD25
+CD127
Low/- in HIV, but not in flu-like infected 
patients, the percentage was similar to that healthy controls, 
indicating that this protocol is not suitable to define Treg in 
HIV patients. 
  Similarly, and related to these differences, absolute 
counts of Treg were not significantly different in PBMC 
from healthy controls and flu-like patients (intragroup 
comparisons) in any of the protocols used (data not shown), 
but varied in HIV-infected patients; in the HIV-U group the 
Treg counts were 202 cells/μl (142-243 cells/μl) and 163 
cells/μl (116-235 cells/μl) when the Treg were defined as 
CD4
+Foxp3
+, and CD4
+Foxp3
+CD127
Low/- respectively; 
however, the counts were significantly lower, only 117 
cells/μl (96-178 cells/μl), when these cells were defined as 
CD4
+CD25
+CD127
Low/-  (Fig.  2B; p<0.01 compared to 
CD4
+Foxp3
+). Similarly, in the HIV-VL group the count of 
Treg defined as CD4
+CD25
+CD127
Low/-  was significantly 
lower than CD4
+Foxp3
+ (107 cells/μl (58-187 cells/μl)  vs 
(173 cells/μl (108-360 cells/μl); p<0.001) and 
CD4
+Foxp3
+CD127
Low/-  (107 cells/μl (58-187 cells/μl)  vs 
(179 cells/μl (104-269 cells/μl); p<0.01) (Fig. 2B). In 
PBMC, HIV patients exhibited the highest Treg counts 
(Foxp3
+), compared to controls (HIV-U: 202 cells/μl vs HC: 
101 cells/μl; and HIV-VL: 173 cells/μl vs HC: 101 cells/μl; 
both p<0.05). 
  GALT is the primary site of damage during HIV 
infection, where the virus induces many quantitative and 
functional changes in the Tcon subset [22]. Therefore, we 
also analyzed biopsy samples of this tissue. When the 
frequency of Treg was evaluated in GALT samples from 
HIV patients, the differences, depending on the protocol 
used, were more evident. In both groups of HIV-infected 
individuals the Treg percentage in GALT were similar when 
the Treg were defined as CD4
+Foxp3
+, and CD4
+Foxp3
+ 
CD127
Low/-; however, when these cells were defined as 
CD4
+CD25
+CD127
Low/-, a significant decrease in the 
frequency were observed compared to CD4
+Foxp3
+ (HIV-U: 
8% (5-15%) vs 14% (12-16%) or HIV-VL: 12% (7-14%) vs 
18% (16-27%); p<0.001) (Fig. 2C). Again, in healthy 
controls the percentage of Treg in GALT was similar 
independent of the protocol used (Fig. 2C, upper panel), and 
the Treg frequency was significantly lower compared to HIV 
patients, using CD4
+Foxp3
+CD127
Low/-  or CD4
+Foxp3
+ 
protocols (both, p<0.001). No differences were observed 
using the CD4
+CD25
+CD127
Low/-  protocol. The Treg 
frequency in GALT was not measured in flu-like patients. 
  The comparison between tissues showed that the Treg 
frequency increases in GALT compared to peripheral blood 
in all 3 groups tested: controls, HIV-U and HIV-VL; the 
increase was ~1.7, ~2, ~2.4 times, respectively, when the 
protocols CD4
+Foxp3
+  (p=0.001) and CD4
+Foxp3
+ 
CD127
Low/- (p=0.003) were used. Treg identification with the 
protocols CD4
+Foxp3
+ and CD4
+Foxp3
+CD127
Low/-  in 
PBMC (r=0.80, p=0.0001) and GALT (r=0.82, p=0.0001) 
from HIV patients exhibit the highest positive correlation 
(Fig. 3A, B), indicating that both protocols are suitable to 
determine Treg frequency in these samples. 
HIV-1 Infected Patients Exhibit Alteration in the 
Expression of CD25
 Molecule in CD4
+Foxp3
+ T Cells in 
Peripheral Blood and Rectal Tissue 
  To evaluate potential variations in the Treg phenotype, 
the expression of CD25 was analyzed in the Foxp3 CD4
+ 
gate. We measured the percentage of cells expressing this 
molecule and the mean MFI of its expression (Fig. 1B). As 
shown in Fig. (4A), the percentages of CD25
+ Treg cells are 
lower in HIV patients compared with healthy controls and 
flu-like patients. In the HIV-U, the percentages of CD25
+ 
cells were 42% (35-58%) and 33% (27-47%) in PBMC and 
GALT respectively; in HIV-VL these percentages 
correspond to 39% (25-40%) in PBMC and 35% (26-49%) 
in GALT, compared to 56% (51-64%) and 47% (35-53%) in 
PBMC and GALT, respectively, in cells from controls. In 
fact, the percentage of CD25
+ Treg from HIV patients (with 
or undetectable VL) was about ~1.4-fold lower than from 
controls in both PBMC and GALT (p<0.05) (Fig. 4A, lower 
panel). The percentage of CD25
+ Treg in PBMC from flu-
like patients was 58% (51-60%), similar to controls (Fig. 4A, 
middle panel). Analyzes of CD25 in Tcon (CD4
+Foxp3
-) 
showed that the percentage of CD25
+ in PBMC and GALT 
increases in cells from HIV patients (data not shown), 
suggesting that the low expression of CD25
+ occurs only in 
the Treg subset. 
CD25
+ Treg from HIV-1 Patients with Detectable Viral 
Load and Flu-Like Infected Individuals Exhibit Higher 
Density of the CD25 Molecule 
  We then examined whether the reduction of the CD25 
molecule in Foxp3
+CD4
+ cells from HIV patients affects not 
only the percentage of cells expressing this molecule but also 
the density of its expression per cell. As shown in Fig. (4B), 
the CD25 MFI in Treg from control samples was 17 (13-20) 
and 11 (8-16), in PBMC and GALT, respectively; in HIV-U Low Frequencies of CD25+ Treg During HIV Infection  The Open Virology Journal, 2012, Volume 6    53 
the CD25 MFI was 35 (18-60) and 15 (9-57). Although in 
these patients the range was very wide, no significant 
differences were found in HIV-U vs HC. 
  In contrast, patients with acute flu-like or HIV chronic 
infection with detectable viral load exhibits the highest levels 
of CD25 MFI, compared with controls. In flu-like samples, 
the CD25 MFI was 75 (64-88) in PBMC; it was 87 (51-97) 
and 62 (16-76) in HIV-VL samples from PBMC and GALT, 
respectively (Fig. 4B). These results suggest that viral 
replication could modify the density of the expression of 
CD25 molecule on Treg. To evaluate the strength of the 
association between the Treg phenotype and viral load, 
Fig. (2). Frequency of Treg CD4
+Foxp3
+, CD4
+Foxp3
+CD127
Low/-  and CD4
+CD25
+CD127
Low/-  in samples from healthy controls, 
individuals with acute flu-like symtoms, chronically HIV-infected with or undetectable  viral load. Whisker box figures show 
phenotypic characterization of Treg. A) Percentage of Treg from PBMC of healthy controls (n=13) (upper panel), flu-like symptoms patients 
(n=9) (middle panel), HIV-U (n=13) (middle panel) and HIV-VL (n=19) (lower panel). B) Treg absolute count in PBMC samples from HIV-
U and HIV-VL patients. C) Percentage of Treg from GALT of healthy controls (upper panel), HIV-U (middle panel) and HIV-VL (n=10) 
(lower panel). Median and 25-75 interquartiles ranges are represented. Intra groups were compared by the Friedmann test and Dunn’s 
multiple post-test. Signiﬁcant differences are indicated by *p < 0.05, **p < 0.01, ***p < 0001. 
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correlations were examined in HIV+ patients. Interestingly, 
the CD25 MFI in Treg from PBMC and GALT was 
positively correlated with viral replication (PBMC r=0.45, 
p= 0.03; GALT r=0.71, p=<0.0001) (Fig. 4C). 
  Finally, we analyzed whether the changes on the CD25 
expression on Treg was due to an alteration in the expression 
of the transcription factor Foxp3 (Fig. 1C); the MFI of 
Foxp3 was similar among Treg from controls, flu and HIV 
patients on both tissues (PBMC; p=0.635 and GALT; 
p=0.802), ruling out this possibility (Fig. 5). 
  In conclusion, these results indicate that Treg from 
chronic HIV infected patients exhibit an alteration in the 
expression of the CD25 molecule, resulting in a reduced 
percentage of CD25
+ cells. This finding suggests that 
detection of Treg based only in the expression of the CD25 
molecule, could result in an underestimation of the 
Fig. (3). Correlations between the different protocols to characterize the Treg cells in samples from PBMC and GALT. Spearman 
correlations between Treg frequency charactized by CD4
+Foxp3
+ and CD4
+Foxp3
+CD127
Low/- in A) PBMC. B) and GALT. 
Fig. (4). Percentage and MFI of CD25 molecule of Treg in samples from healthy controls, chronically HIV-infected and individuals 
with acute flu-like symptoms. A) Pie charts show the percentage of Treg (CD4
+Foxp3
+) expressing the CD25 (CD4
+Foxp3
+CD25
+) or 
negative for the CD25 molecule (CD4
+Foxp3
+CD25
-) in PBMC and GALT samples from controls (n=10), HIV-U (n=13); HIV-VL (n=19), 
and in PBMC from flu-like patients (n=9). B) Whisker box figures show MFI of CD25 in Treg (in the gate of CD4
+Foxp3
+CD25
+) in PBMC 
and GALT samples; median and interquartile ranges are represented. C) MFI of CD25 of Treg in PBMC and GALT were positively 
correlated with HIV viral load. Groups were compared by the Kruskal Wallis test and Dunn’s multiple comparisons post-test. Signiﬁcant 
differences are indicated by **p < 0.01, ***p < 0001. 
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frequency of this cell subset in HIV infected individuals. On 
the other hand, the higher intensity of CD25 expression per 
cell within the positive cell subpopulation could be 
associated with the chronic state of hyperactivation during 
HIV infection. 
 
Fig. (5). MFI of the transcription factor Foxp3 on samples from 
healthy controls, chronically HIV-infected and individuals with 
acute flu-like symtoms. Whisker box figures show MFI of Foxp3 
in Treg in PBMC and GALT samples from controls (n=10) and 
HIV patients (HIV-U n=13; HIV-VL n=19), and in PBMC from 
flu-like patients (n=9). Groups were compared by the Kruskal 
Wallis test and Dunn’s multiple comparisons post-test. 
DISCUSSION 
  Since the description of Treg, their phenotypic 
characterization has been complex; in the beginning, high 
expression of CD25 in the CD4
+ T cell subset was widely 
used to characterize them. Unfortunately, the ability to 
accurately gate for CD25 is rather arbitrary and the 
expression of this molecule is not specific to Treg. Several 
studies demonstrated that low or negative CD127 expression 
is an excellent biomarker of Treg, particularly in 
combination with CD25 or Foxp3. In fact, CD127 and CD25 
stain allows human Treg enrichment for in vitro functional 
studies [23, 24]. So far, the combination of CD25, CD127 
and Foxp3 expression is considered the best way to 
distinguish between human Treg and CD4
+ Tcon [23]. 
According to previous studies, similar percentages of Treg 
were reported when these cells were defined with the 
combination of these molecules (CD25
+Foxp3
+; 
CD25
+CD127
Low/-, Foxp3
+CD127
Low) in basal conditions in 
PBMC and lymphoid nodes from adults, children and cord 
blood from neonates, without infection or metabolic diseases 
[16]. 
  In addition, the characterization of Treg in patients with 
viral respiratory acute infections is largely unknown. During 
the first week of influenza H1N1 [25, 26] and influenza A 
[27] infection an increase in the frequency of Treg in PBMC 
were reported. In agreement with these results, we also 
observed high frequency of Treg in patients with flu-like 
symptoms compared to uninfected controls. No differences 
were observed in the protocol used to identify these cells. 
Unfortunately, we could not obtain respiratory tract samples 
from the flu-like patients to compare with PBMC. 
  In contrast to controls and patients with flu-like illness, in 
this study the analysis of Treg in chronic HIV infected 
individuals shows that the frequency of this cell 
subpopulation varies depending on the protocol used; in 
particular, the detection of CD25
+CD127
Low/- cells produced 
a lower frequency of Treg compared to the protocols in 
which the detection of Foxp3 was included. In this respect, 
Bi et al., 2009 described that gating CD4
+CD25
+/hiCD127
Low 
was difficult to analyze because staining showed a smear of 
both CD25 and CD127 and proposed that gaiting Foxp3 in 
CD4 cells gave a clearer staining [28]. In accordance to this 
previous report, our results also indicate that the 
identification of Treg cells in samples from HIV patients 
should rely in the detection of the marked Foxp3 alone or in 
combination with CD127; in fact, these two protocols 
showed the highest correlation in both types of samples. 
Although the CD25 molecule is a key phenotypic and 
functional marker of Treg, the detection of this cell subset 
based on its expression might result in underestimation of 
these cells. 
  In accordance with our results, Ndhlovu  et al., 2008 
reported a similar frequency of Treg, defined as CD25
+ 
CD127
Low/-  cells in PBMC in HIV patients, with both 
primary and chronic infection, and controls; however, when 
these authors characterized these cells as Foxp3
+CD127
Low/-, 
the patients exhibited an increase of this subset compared to 
controls [10]. In this report, the authors hypothesized that 
HIV patients contain different sub-subsets of Treg with 
different phenotypes and functions. Also, Pozo-Balado et al., 
2010 reported that the CD4
+CD25
+/hiCD127
Low  phenotype 
does not accurately identify Treg in PBMC from viremic 
patients [29]. However, in this report the comparison did not 
include healthy controls or Foxp3
+, Foxp3
+CD127
Low/- 
analysis. In samples from GALT, epple et al., 2006 [5] and 
Shaw et al., 2011 demonstrated that the frequency of Treg 
was consistently higher in HIV patients with high viral loads 
compared to seronegatives [30]. However, in peripheral 
blood, the detection of Treg with the CD25
+CD127
lo protocol 
indicated a lower frequency of these cells in HIV patients 
with undetectable viral load (controllers) compared to 
uninfected individuals [30]. Together, these data are in 
agreement with the fact that Treg increase during HIV 
infection and their characterization changes 
depending on how these  cells  are analyzed,  indicating  that 
classic strategies to detect Treg cells might be suitable, but 
carefully considered, depending on the type of viral 
infection. 
  The results of the present study suggest that there is an 
expansion/accumulation of Treg during HIV infection in 
both peripheral blood and GALT tissue; the expanded cells 
exhibit an altered expression of the CD25 molecule. Indeed, 
it was previously shown that the percentage of Treg in 
PBMC expressing the CD25 molecule (Foxp3
+CD25
+) is 
about 45% in controls and 34% in HIV patients [31]. 
Interestingly, the majority of evidence indicating the low 
frequency of CD25 in Treg is reported particularly in tissue 
samples [5, 32, 33]. In fact, using immunohistochemistry and 
immunofluorescence analyses in samples from lamina 
propia, lower CD25 expression in Foxp3
+ cells has been 
reported [5]. Confocal micrographs from tonsillar biopsies 
have shown Foxp3
+CD25
+ percentages of 19%, 44%, and 
75% in HIV progressors, non progressors, and uninfected 
donors, respectively [33]. Other reports on tonsillar biopsies 
detected only a 19% and 16% of Foxp3
+CD25
+ cells in HIV-
untreated and treated patients, respectively [32]. Analysis of 
CD25
+ and CD25
 CD4
+ T cells from in spleens and lymph 
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nodes of SIV-infected macaques, confirm that the population 
of Foxp3 expressing cells in lymphoid tissues is not limited 
to a CD25
+ phenotype and that CD25
 Foxp3
+ may be 
present in lymphoid tissues during chronic infection [34]. 
Unfortunately, comparisons in the frequency of Treg using 
different phenotypic markers were not performed by these 
authors. Although previous findings have demonstrated a 
decrease in the expression of CD25, this article along with 
the recently published by Shaw et al., [30] are the only ones 
that include a comparison of different current protocols for 
identifying Treg cells in peripheral blood and GALT samples 
in HIV infected patients. 
  In the present study we report that significant changes in 
the CD25 expression occur in Treg from HIV patients in 
both at the percentange of cells expressing this molecule and 
at the density of expression, measured in terms of MFI. 
Experimental evidence suggest several possibilities to 
account for this observation: (i) chronic expansion of Treg in 
vivo results in low levels of CD25 expression, retaining their 
suppressive activity, as previously reported in a murine 
model [35]; this constant expansion (high Treg frequency) is 
observed also in GALT from HIV infected patients [5, 30]; 
(ii) it might reflect internalization of the CD25 molecule 
after IL-2 binding [36]; in fact, the expansion of 
CD4
+CD25
loCD127
loFoxp3
+ Treg is one of the long-term 
effects of IL-2 therapy in HIV patients [37, 38]; (iii) in vitro 
assays have shown that HIV induces down regulation of the 
CD25 molecule in CD4
+ infected cells [39]. In addition, HIV 
viral proteins are involved in this process, inhibiting IL-2R 
expression; HIV p29 protein induces a two fold increase in 
the intracellular cyclic adenosine 3’,5’-monophosphate 
(cAMP) in PBMC which is associated with the decrease of 
CD25 [40]. HIV Tat protein and the Gp120 also decrease the 
expression of this molecule in Jurkat cells line [41] and 
CD4
+ T cells [42], respectively. 
  On the other hand, it is important to note that CD25 
expression per cell in Treg from HIV-untreated and flu-like 
patients increases compared to controls despite similar levels 
of Foxp3 expression, suggesting a competitive advantage for 
IL-2, reducing the available levels of this cytokine in the 
microenvironment [43]. The increase of CD25 MFI can be 
explained as a consequence of cellular activation; CD4
+ T 
cells exposed to HIV upregulated the expression of CD25, in 
Tcon (CD4
+CD25
-) [44] and in Treg (CD4
+CD25
+) cells 
[33], along with the expression of other activation molecules 
such as HLA-DR [45, 46]. In fact, there was a positive 
correlation between the CD25 MFI and the viral load, 
supporting that HIV induces activation of CD4
+  and Treg 
cells as previously reported [46, 47]. Interestingly, the MFI 
of CD25 in HIV-U was lower compared to HIV-VL patients, 
supporting the idea that cellular activation is partially 
controlled by antiretroviral treatment [48]. 
  In conclusion, here we report an additional phenotypic 
alteration of Treg from HIV patients. The percentage of Treg 
expressing CD25 decreases, making the detection of this 
molecule an unsuitable tool to characterize Treg in HIV 
patients, particularly in tissue samples. The data presented 
here also suggest that the use of flow sorting and magnetic 
columns to deplete Treg based on the expression of CD25 
[49, 50] does not ensure complete elimination of this cell 
population, which may affect functional assays. Although we 
are aware that the sample size was limited, and the results 
required further verification, these results point to the urgent 
requirement to develop additional methods to deplete Treg 
from PBMC, as a way to measure the role of this cell 
subpopulation in the context of chronic infections, in 
particular HIV. 
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ABBREVIATIONS 
PBMC  =  Peripheral blood mononuclear cells 
GALT  =  Gut associated lymphoid tissue 
RC =  Rectal  cells 
Tregs =  Regulatory  T  cells 
Tcon  =  Conventional T cells 
HC =  Healthy  controls 
HIV =  Human  immunodeficiency  virus 
FLU  =  Individuals with acute flu-like symptoms 
HAART  =  Highly active antiretroviral therapy 
VL =  Viral  load 
FCS  =  Fetal calf serum 
DPBS  =  Dulbeco´s phosphate buffered saline 
MFI =  Mean  fluorescence  intensity. 
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